Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Autologous Stem Cell Transplantation (ASCT) is aggressive, high-dose chemotherapy. Study after study confirms that ASCT does NOT give multiple myeloma patients a longer overall-survival (OS) on average.
Further, aggressive, high-dose chemotherapy mean lots of toxicity. Toxicity means side effects- short, long-term and late stage.
According to the study linking and excerpted below, there is NO difference in patient length of life aka Overall Survival when comparing transplantation now or later.
What the myeloma patient gains with an early ASCT is a longer progression-free survival (PFS). Meaning your remission, on average, is deeper and longer than otherwise.
So the choice of the newly diagnosed multiple myeloma patient is to have an ASCT and hopefully achieve a deep, long remission while experiencing short, long-term and late stage side effects or wait and live with fewer side effects and possibly experience remission and relapse.
I was originally diagnosed with multiple myeloma in early 1994. I had an ASCT in 12/95. My remission lasted for about 10 months. I live with long-term and late stage side effects from my conventional therapies.
I have remained in complete remission since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health and more.
Click the button on the right of the page to watch a free webinar about the MM Cancer Coaching Program that I researched and designed base on my 20 plus years living with Multiple Myeloma.
Scroll down the page, post a question or a comment and I will reply to you ASAP.
“The results show that after induction with lenalidomide (Revlimid, Celgene), bortezomib (Velcade, Takeda), and dexamethasone (RVD) (multiple brands), survival for patients who received transplants as part of consolidation therapy was similar to that for patients who received transplants following relapse…
However, progression-free survival (PFS) and response rates were higher for patients in the early transplant group…
“This benefit must be weighed against the increased risk of toxic effects associated with high-dose chemotherapy plus transplantation, especially since we found that later transplantation might be as effective as early transplantation in securing long-term survival,” the investigators concluded…
He indicated that with respect to timing, the study showed that overall survival was similar for patients who received transplants early or late (at time of relapse)…
Implications for Clinical Practice
In one way, the results of the study may well reflect clinical practice.
Dr Schiffer told Medscape Medical News that the study data show no clear advantage with early transplant. “Some patients in the study haven’t needed a transplant. There may be a benefit from delaying transplantation,” he said.